Table 5.

Ongoing randomised studies in oligometastatic NSCLC

	SARON	OMEGA	CORE	PROMISE-005	NRG LU 002	Current study
Trial ID	NCT02417662	NCT03827577	NCT02759783	NCT03808337	NCT03137771	CTRI/2020/04/024761
Country	UK	Italy	UK	USA	Multicentric	India
Trial design	RCT III	RCT III	RCT II/III	RCT II	RCT II/III	RCT III
OM sites (n)	≤3	≤3	≤3	≤5	≤3	≤5
Presentation Primary Site Oncogene mutation	Synchronous at least 1 extracranial site NSCLC Negative*	Synchronous or metachronous NSCLC Negative and Positive	Metachronous Breast, Prostate, NSCLC –	Synchronous or metachronous TNBC, NSCLC Negative and Positive	Synchronous or metachronous (extracranial) NSCLC Negative	Synchronous NSCLC Negative
Target accrual	340	195	245	142	300	206
Control arm Experimental arm	SMT RT to primary and SBRT for OM	Systemic therapy Systemic therapy followed by LAT	SOC SBRT followed by SOC	SOC SBRT plus SOC	SMT LCT+SMT	SMT LCRT+SMT
Primary end point	OS	OS	PFS/OS	PFS	PFS/OS	OS
Estimated year of completion	2022	2022	2024	2022	2022	2024

*Negative indicates for de-novo stage IV non-small cell lung cancer.

LAT, local ablative therapy; LCRT, local consolidation radiation therapy; NSCLC, non-small cell lung cancer; OM, oligometastases; OS, overall survival; PFS, progression-free survival; RCT, randomised controlled trial; SBRT, stereotactic body radiation therapy; SMT, standard maintenance therapy; SOC, standard of care; TNBC, triple-negative breast cancer.